

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Shilpa Medicare and Gate2Brain sign strategic equity partnership to advance brain cancer therapy

09 June 2026 | News

To bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories



Raichur-based Shilpa Biocare, a subsidiary of Shilpa Medicare, has entered a strategic equity partnership with Spain-based Gate2Brain, S.L., a biotechnology company focused on central nervous system (CNS) therapeutics.

Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead programme targeting deadly paediatric brain cancers, paediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG), both with Orphan Drug Designation from the US FDA and EMA.

G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28.

G2B-002 targets high-growth oncology markets — the glioblastoma market projected at \$6.48 billion by 2035 (CAGR: 7.97%), paediatric brain tumours at \$2.47 billion by 2031 (CAGR: 6.9%), and DIPG at \$1.2 billion by 2035 (CAGR: 7.1%).

Gate2Brain's MiniAp4 platform further extends potential across rare paediatric cancers and broader CNS categories. This marks Shilpa's fourth strategic equity partnership.